Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;8(3):231-9.
doi: 10.1007/s10689-009-9233-0. Epub 2009 Jan 23.

Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer

Affiliations

Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer

Kristen M Drescher et al. Fam Cancer. 2009.

Abstract

The ability of the host to mount an appropriate immune response to aberrant cells is one factor that determines prognosis in cancer patients. Naturally occurring regulatory T cells (T regs; CD4+ CD25+ cells) are key regulators of peripheral tolerance. It has been suggested that high levels of T regs are detrimental to the patient in some forms of cancer, but the role of these antigen-specific cells in individuals with colorectal cancers with high levels of microsatellite instability is unknown. Herein, we examined the ability of individuals with MSI-H or microsatellite stable colon cancer to recruit lymphocytes to the tumor site. Immunohistochemical staining was performed on archived paraffin-embedded specimens from a total of 38 individuals with MSI-H (n = 25) or MSS (n = 13) colon cancers to determine the proportion of CD3+, CD8+ and CD25+ cells infiltrating the tumor site. Patients with MSI-H colon cancers had increased percentages of CD8+ TILs (cytotoxic T cells) as compared to individuals with MSS colon cancer (47.3 vs. 24.04% of the infiltrate CD8+, respectively). No differences in the levels of CD25+ T cells were observed between individuals with MSI-H colon cancers and MSS colon cancers (0.53 vs. 0.54% CD25+, respectively). Together, these data suggest that the survival advantage enjoyed by patients with MSI-H colorectal cancer may, in part, be attributed to the increased cytolytic response, but not to an antigen-specific immunosuppressive response in MSS patients.

PubMed Disclaimer

References

    1. Int J Oncol. 2003 Aug;23(2):429-36 - PubMed
    1. J Pathol. 2002 Jan;196(1):67-75 - PubMed
    1. Cancer. 2006 Dec 15;107(12):2866-72 - PubMed
    1. Oncol Rep. 2005 Nov;14(5):1269-73 - PubMed
    1. J Pathol. 1997 Jul;182(3):318-24 - PubMed

Publication types